Wolverine Trading
AMLX icon

Wolverine Trading’s Amylyx Pharmaceuticals AMLX Stock Holding History

Wolverine Trading’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,571
Closed -$22.4K – 4418
2024
Q1 		$32.9K Buy
+11,571
New +$151K ﹤0.01% 4283

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wolverine Trading's AMLX Position: Q2 2024 in Review

Wolverine Trading sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2024, closing a stake of 11,571 shares — an estimated $22.4K sold.

Wolverine Trading first reported a position in AMLX in Q1 2024 and held it in 1 quarter. The position peaked at $32.9K in Q1 2024. 119 funds tracked by Wall St. Rank hold AMLX as of Q2 2024.

  • Wolverine Trading reported no remaining Amylyx Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Wolverine Trading sold 11,571 Amylyx Pharmaceuticals shares in Q2 2024, an estimated $22.4K.
  • Wolverine Trading first reported a position in Amylyx Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Wolverine Trading's Amylyx Pharmaceuticals position peaked at $32.9K in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2024.

Based on Wolverine Trading's 13F filing for Q2 2024, filed 14 Aug 2024.